BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 1493717)

  • 21. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
    Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
    Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levonorgestrel levels in serum and uterine flushings in women bearing LNG-Cu-IUD.
    Shi JP; Wu XR
    J Tongji Med Univ; 1993; 13(2):126-8. PubMed ID: 8230357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Levonorgestrel IUD].
    Skajaa K; Forman A
    Ugeskr Laeger; 1994 Nov; 156(46):6884-7. PubMed ID: 7839510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recovery of fertility after use of the levonorgestrel 20 mcg/d or Copper T 380 Ag intrauterine device.
    Belhadj H; Sivin I; Diaz S; Pavez M; Tejada AS; Brache V; Alvarez F; Shoupe D; Breaux H; Mishell DR
    Contraception; 1986 Sep; 34(3):261-7. PubMed ID: 3098498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery.
    Critchley HO; Wang H; Jones RL; Kelly RW; Drudy TA; Gebbie AE; Buckley CH; McNeilly AS; Glasier AF
    Hum Reprod; 1998 May; 13(5):1218-24. PubMed ID: 9647550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NORPLANT and the levonorgestrel IUD in Chinese family planning programmes.
    Xiao BL; Gu SJ; Wang SL; Zhu PD; Shi SQ
    Ann Med; 1993 Apr; 25(2):161-5. PubMed ID: 8489754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early chorionic activity in women bearing inert IUD, copper IUD and levonorgestrel-releasing IUD.
    Videla-Rivero L; Etchepareborda JJ; Kesseru E
    Contraception; 1987 Aug; 36(2):217-26. PubMed ID: 3123135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fertility after discontinuation of levonorgestrel-releasing intrauterine devices.
    Nilsson CG
    Contraception; 1982 Mar; 25(3):273-8. PubMed ID: 6804163
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
    Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
    Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endometrial morphological changes in IUD users: a review.
    Sheppard BL
    Contraception; 1987 Jul; 36(1):1-10. PubMed ID: 3117492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cervical carcinogenesis and contraception.
    Misra JS; Engineer AD; Das K; Tandon P
    Diagn Cytopathol; 1991; 7(4):346-52. PubMed ID: 1935511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intrauterine devices. The optimal long-term contraceptive method?
    Fortney JA; Feldblum PJ; Raymond EG
    J Reprod Med; 1999 Mar; 44(3):269-74. PubMed ID: 10202746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].
    Imperato F; Perniola G; Mossa B; Marziani R; Perniola F; Stragapede B; Napolitano C
    Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparative study on the clinical effects and endometrial findings of IUD].
    Chao CK
    Toho Igakkai Zasshi; 1988 Mar; 34(6):550-60. PubMed ID: 12343145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.
    Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium
    Lancet; 2019 Jul; 394(10195):303-313. PubMed ID: 31204114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices.
    Toivonen J; Luukkainen T; Allonen H
    Obstet Gynecol; 1991 Feb; 77(2):261-4. PubMed ID: 1899136
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study.
    Bosco-Lévy P; Gouverneur A; Langlade C; Miremont G; Pariente A
    Contraception; 2019 Jun; 99(6):345-349. PubMed ID: 30871933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of copper intrauterine device with levonorgestrel-bearing intrauterine system for post-abortion contraception.
    Bilgehan F; Dilbaz B; Karadag B; Deveci CD
    J Obstet Gynaecol Res; 2015 Sep; 41(9):1426-32. PubMed ID: 26180028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol.
    Suvanto-Luukkonen E; Sundström H; Penttinen J; Kauppila A
    Arch Gynecol Obstet; 1998; 261(4):201-8. PubMed ID: 9789651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.